Abstract Myeloid-derived suppressor cells (MDSC) are important regulators of the immune system and key players in tumor-induced suppression of T-cell responses. CD14+HLA-DR¡/low MDSC have been detected in a great number of malignancies, including melanoma. MDSC are known to be impaired in their ability to diVerentiate along the myeloid lineage, e.g., into dendritic cells (DC). This is a concern for utilization of monocyte-derived DC for vaccination of patients with melanoma or other cancers exhibiting accumulation of CD14+ MDSC. When producing DC according to standard operating procedures of two currently ongoing clinical trials, we found that MDSC co-puriWed with monocytes isolated by elutriation. MDSC frequencies did not aVect yield or viability of the produced DC, but induced a dose-dependent decrease in DC maturation, ability to take up antigen, migrate and induce T-cell IFN production. Changes in DC characteristics were most notable when 'pathological' frequencies of >50% CD14+ HLA-DR¡ cells were present in the starting culture. The impaired DC quality could not be explained by altered cytokine production or increased oxidative stress in the cultures. Tracking of HLA-DR¡ cells throughout the culture period revealed that the observed changes were partially due to the impaired maturation and functionality of the originally HLA-DR¡ population, but also to their negative eVects on HLA-DR+ cells. In conclusion, MDSC could be induced to diVerentiate into DC but, due to the impairment of overall DC vaccine quality when >50% HLA-DR¡ cells were present in the starting culture, their removal could be advisable.
Introduction
Myeloid-derived suppressor cells (MDSC) are potent immune regulators with a broad arsenal of suppressive mechanisms (for a recent review see [1, 2] ). By deWnition, they are a heterogeneous population of immature, immunosuppressive cells of myeloid origin, containing dendritic cell (DC), macrophage and granulocyte precursors.
The physiological role of MDSC is thought to lie in the regulation of immune responses to infection and after traumatic stress [3] [4] [5] . However, increased frequencies of immature myeloid cells with suppressive functions have also been observed in many diVerent types of cancer [6] [7] [8] [9] [10] [11] [12] [13] [14] .
While mouse MDSC have been well studied, human MDSC remain elusive since their phenotype is still debated and seems to vary between diVerent types of cancers. CD14+HLA-DR¡/low MDSC have been described in melanoma [7, 12] , as well as in hepatocellular carcinoma [9] , prostate cancer [14] , glioblastoma [8] , multiple myeloma [6] and non-Hodgkin lymphoma [10] . We have previously shown that CD14+HLA-DR¡/low MDSC in melanoma are distinct from normal monocytes and potently suppress autologous T cells.
At physiological MDSC-T cell ratios, proliferation as well as IFN production of CD4 and CD8 T cells was strongly suppressed. The mechanisms of suppression included overexpression of Arginase 1, as well as production of reactive oxygen species, and were dependent on the signal transducer and activator of transcription (Stat3) [12] .
A number of studies have shown that MDSC are arrested in an immature state and poorly diVerentiate along the DC or macrophage lineage even in the presence of cytokines or diVerentiating agents such as all-trans retinoic acid [11, 15] . Recruitment of MDSC by tumor-derived factors in combination with their inability to fully diVerentiate represent mechanisms underlying the observation that immature myeloid cells are frequently over-represented in the circulation of cancer patients, while the number of mature myeloid cells is reduced [16, 17] .
DC vaccination is an active immunization approach that holds promise for the treatment of cancer and is currently under intense investigation. Since DC are professional antigen-presenting cells, they can be Xexibly loaded in vitro and in vivo with many diVerent types of antigen and should exhibit potent T-cell stimulatory activity. A large number of clinical trials utilizing DC in combination with a variety of antigen formulations and co-stimulatory entities are currently ongoing and have shown some clinical success (reviewed in [18] ; [18] [19] [20] [21] ).
In light of many ongoing clinical trials making use of monocyte-derived DC as vaccines in cancer patients, we studied whether CD14+HLA-DR¡/low MDSC could interfere with the successful generation of DC vaccines. We discovered that high frequencies of CD14+HLA-DR¡/low cells in the starting monocyte population could inhibit DC maturation and result in DC impaired in functions considered to be important for vaccine success.
Materials and methods

Patient material
Five patients with stage IV malignant melanoma (1 male, 4 female; mean age 48 years, range 34-74 years) were included in this study. Patients underwent leukapheresis and fractions of the leukapheresis product were used to isolate monocytes and generate DC. These patients were the Wrst Wve included in the EUDRACT #2008-000694-38 phase I clinical trial combining DC vaccination with adoptive T-cell transfer. All patients had previously received treatment for their disease, but no treatment was administered in the 4 weeks preceding the leukapheresis. The Regional Ethical Review Board at Karolinska Institutet, Stockholm, approved this study. Informed consent was mandatory.
Cell isolation and co-culture setup Monocytes and lymphocytes were isolated from the leukapheresis product by elutriation (counterXow centrifugation), using an Elutra™ (Gambro, Stockholm, Sweden). Five cellular fractions were collected at 37 mL/min, 97.5 mL/min, 103.4 mL/min and 103.9 mL/min at 2,400 rpm and at 103.9 mL/min with the rotor oV. Fraction 5 contained >68% CD14+ cells in all cases (mean purity 82%). HLA-DR positive and negative populations were separated using anti-HLA-DR magnetic beads (Miltenyi, Bergisch Gladbach, Germany) according to the manufacturers' instructions. PuriWed HLA-DR+ and HLA-DR¡ cells were mixed to attain HLA-DR¡ frequencies of 0, 10, 20, 50, 70 or 100%. To follow the HLA-DR+/¡ populations during the co-culture, in some experiments either the HLA-DR+ (p003, p005) or HLA-DR¡ (p004) fraction was labeled with lipophilic carbocyanine DiOC 18 (DiR) (Invitrogen, Carlsbad, USA) prior to mixing the two populations. Cells were incubated with 0.875 g/mL DiR in PBS (GIBCO, Invitrogen, Carlsbad, USA) for 10 min at 37°, then washed 3£ in CellGro medium (Cell-Genix, Freiburg, Germany).
DC generation
Two protocols were employed to generate DC. The 'long-DC' protocol reXects the protocol employed for the GMP grade production of DC in the EUDRACT #2008-000694-38 clinical trial. Here, monocytes were cultured in CellGro medium at 2 million cells/mL in VueLife 32-C cell culture bags in the presence of 100 ng/mL granulocyte macrophage colony-stimulating factor (GM-CSF) and 20 ng/mL interleukin (IL)-4. On day 2 of culture, one volume of fresh cytokine-containing medium was added. On day 5, immature DC (iDC) were harvested, counted and characterized. The remaining cells were adjusted to 2 million cells/mL in medium with IL-4 and GM-CSF as above, then iDC were matured by the addition of 20 ng/ mL tumor necrosis factor (TNF)-. On day 7, mature DC (mDC) were harvested, counted, characterized and frozen if suYcient numbers were available. All culture media, cytokines and plastics were from CellGenix (Freiburg, Germany).
The 'fast-DC' protocol is a modiWed version of the DC generation protocol employed in the phase II TAPCell vaccination protocol as described previously [22, 23] . BrieXy, 2 million monocytes/mL were cultured in AIM-V medium (GIBCO, Invitrogen, Carlsbad, USA) in six-well plates. The medium was supplemented with 100 ng/mL GM-CSF and 20 ng/mL IL-4. After 48 h, iDC were matured by the addition of 20 ng/mL TNF-(all cytokines from CellGenix, Freiburg, Germany) and 100 g/mL TRIMEL. TRIMEL is a mix of cell lysates generated from three melanoma cell lines after a 1-h heat-shock period; its properties have been described elsewhere [22] . At 24 h after initiation of maturation, mDC were harvested, counted, characterized and frozen if available in suYcient numbers.
Phenotyping
On day 2 and 3 of the 'fast-DC' protocol and day 5 and 7 of the 'long-DC' protocol, DC yield and phenotype were determined. Cell counts including live/dead discrimination with Trypan blue (GIBCO, Invitrogen, Carlsbad, USA) were performed using a Countess automated cell counter (Invitrogen, Carlsbad, USA).
Multiparametric Xow cytometry was applied to characterize the cellular phenotype. The antibody details are provided in Supplemental Table 1 . Extracellular staining was performed for 20 min in 96-well v-bottom plates. All staining and washes were performed in the dark, in PBS + 1% human serum albumin (HSA, Octapharma, Stockholm, Sweden) at 4°C.
Cells were analyzed using an LSRII Xow cytometer (BD Biosciences, San Jose, CA) and FlowJo analysis software (Treestar, Ashland, OR).
Antigen uptake 150.000 iDC or mDC in CellGro ('long-DC') or AIM-V ('fast-DC') were incubated for 1 h with 0.4 mg/mL FitcDextran (Sigma-Aldrich, Stockholm, Sweden) at 37° to measure their capacity to take up antigen. Cells incubated on ice served as background controls. After incubation, cells were washed four times in ice-cold PBS containing 1% HSA, then Wxed for 10 min in 3.7% formaldehyde at 4°a nd subsequently stained with anti-HLA-DR and CD83 antibody. The Xuorescence of surface markers and internalized FITC-labeled dextran beads was determined by Xow cytometry. Migration 200.000 iDC or mDC in CellGro ('long-DC') or AIM-V ('fast-DC') were placed in the upper chamber of 24-well plates with trans-well inserts (5 m pore size; Sigma, Stockholm, Sweden). The lower chamber contained medium alone (unspeciWc migration control) or 300 ng/mL CCL-19 and 250 ng/mL CCL-20. Cells were allowed to migrate toward the lower chamber for 3 h at 37°. After 3 h, the cells in the lower chamber were harvested and counted by re-suspending them in 200 L PBS and acquiring cells with the FSC/SSC characteristics of myeloid cells for 1 min on an LSR-II Xow cytometer with the Xow rate set to "high".
Allogeneic lymphocyte stimulation
Ten million/mL thawed lymphocytes from elutriation fraction 2 (65-85% CD3+ cells) were labeled with 2.5 M CFSE (Invitrogen, Carsbad, USA) for 10 min at 37°C in PBS + 5% FCS (GIBCO, Invitrogen, Carsbad, USA), then washed 3£ in large volumes of PBS + 5% FCS; 100.000 CFSE-labeled lymphocytes in AIM-V medium (GIBCO, Invitrogen, Carsbad, USA) were stimulated with allogeneic DC at a lymphocyte:DC ratio of 10:1 for 4 days. Lymphocytes left unstimulated or incubated with 2 L Dynabeads Human T-Activator CD3/CD28 (Invitrogen, Carsbad, USA) were used as negative and positive controls, respectively. After 5 days, supernatants were removed and interferon (IFN) production quantiWed using an IFN ELISA kit according to the manufacturer's instructions (Mabtech, Stockholm, Sweden). Cells were harvested, stained for expression of CD3 and proliferation was analyzed by monitoring CFSE dilutions within the CD3+ population by Xow cytometry.
Cytokine secretion
A Luminex cytometric bead array (Millipore, Billerica, MA, USA) was used according to the manufacturers instructions to measure the levels of IL1 , IL-1 , IL-6, IL-8, IL-10, IL-12(p40), interferon-gamma induced protein (IP)-10 (CXCL10), monocyte chemotactic protein (MCP)-1 (CCL-2), macrophage inXammatory protein (MIP)-1 (CCL4) and vascular endothelial growth factor (VEGF) in cell culture supernatants of mature and immature DC.
Oxidative stress
The intracellular oxidation levels were determined using 5-(and-6)-chloromethyl-2Ј,7Ј-dichlorodihydroXuoresceindiacetate-acetyl-ester (Invitrogen), which is metabolized to Xuorescent (FL-1) 2Ј,7Ј-dichloroXuorescein (DCF) upon oxidation. BrieXy, cells were incubated with 0.25 mol/L 5-(and-6)-chloromethyl-2Ј,7Ј-dichlorodihydroXuoresceindiacetate-acetyl-ester for 10 min at 37°C, washed twice in ice-cold PBS, stained for surface markers and the mean Xuorescence intensity (MFI) of intracellularly retained DCF was determined by Xow cytometry.
Results
MDSC co-purify with monocytes
The generation of monocyte-derived DC requires puriWcation of monocytes, usually from a leukapheresis product. We found that CD14+HLA-DR¡/low cells co-puriWed within the monocyte fraction when leukapheresis products were separated by elutriation (counterXow centrifugation) (Fig. 1a) . The ratio of HLA-DR¡/low to total CD14+ cells was similar in starting leukapheresis material (mean ratio: 0.51 § 0.2) and the fraction used for DC generation (fraction 5, mean ratio: 0.54 § 0.1).
DC yield and viability are not inXuenced by CD14+HLA-DR¡ frequency
To study the inXuence of HLA-DR¡/low cells on DC vaccine generation, we separated HLA-DR+ and HLA-DR¡ cells and re-mixed them at ratios reXecting more physiological (0, 10, 20% HLA-DR¡ cells) or pathological (50, 70 and 100% HLA-DR¡ cells) situations. Two DC vaccine generation protocols were used: the 'fast'-DC protocol uses plastic culture vessels and involves a 48-h diVerentiation period followed by 24 h of maturation induced by a TNF and a strong maturation stimulus (the tumor lysate TRI-MEL). The 'long'-DC protocol makes use of TeXon culture bags, where DC are diVerentiated for 5 days and matured for 2 days by addition of TNF .
A signiWcant and patient-dependent loss of cells and variation in the Wnal DC yield are commonly observed when generating DC from monocytes. We could not observe a clear positive or negative eVect of high HLA-DR¡ frequencies on the yield of iDC (day 2 or 5) or mDC (day 3 or 7) (Fig. 1b) . The viability of harvested cells was generally high and not aVected by the presence or absence of HLA-DR¡ cells (Fig. 1c) .
Upon in vitro culture, CD14+HLA-DR¡/low cells rapidly up-regulate HLA-DR ( [12] and data not shown), making it diYcult to distinguish them from cells that expressed high HLA-DR already at the start of culture. Fluorescent labeling of HLA-DR¡ or HLA-DR+ populations after puriWcation allowed us to follow them throughout the culture period. Frequencies of labeled cells observed when harvesting mDC were close to values expected based on the culture setup (Fig. 1d) . DC maturation is impaired by CD14+HLA-DR¡ cells Next, we studied whether the presence of high frequencies of HLA-DR¡ cells would impair DC maturation. We studied molecules typically used to monitor DC diVerentiation and found a dose-dependent inhibition of DC-Sign, CD80, CD83, CD86 and CD1a expression as a result of increasing percentages of HLA-DR¡ cells in the co-cultures. There were inter-individual variations in expression levels that could be achieved and diVerences between marker expressions at the diVerent time points, but the inhibition mediated by the presence of HLA-DR¡ cells was (1) most clear in iDC and (2) more consistent between iDC and mDC in fast-DC cultures. As an exception from these observations, p002 displayed improved maturation in cultures with high (>50%) starting HLA-DR¡ frequencies on day 7, while HLA-DR¡ dependent impairment of maturation was detectable on day 5 even in this patient. Figure 2a shows representative histograms comparing expression of maturation markers in cultures from patient 003, containing physiological (10%) or pathological (70%) HLA-DR¡ levels. When comparing maturation of HLA-DR¡ and HLA-DR+ populations from the same culture, e.g., in cocultures containing 50% of each subset, it became apparent that HLA-DR¡ cells had impaired maturation capacity. Representative histograms from patient 004 (fast-DC) and patient 003 (long-DC) are shown in Fig. 2b . This maturation impairment of HLA-DR¡ cells was most easily detectable on day 2, but remained true in all patients for at least some of the studied markers at all studied time points. Though CD1a expression in fast-DC of p004 was decreased in originally HLA-DR+ cells compared to originally HLA-DR¡ cells in the fast-DC culture as shown in Fig. 2b , this marker was usually decreased on days 2 and 7 (mean expression in HLA-DR¡ cells was 60-75% of that observed in HLA-DR+ cells), but similar to HLA-DR+ cells on days 3 and 5.
The defect in maturation of HLA-DR¡ cells did not fully account for the reduced maturation observed in the total DC population. A comparison of HLA-DR+ cells co-cultured with 10 or 70% HLA-DR¡ cells showed that in some, but not all, cases, maturation of HLA-DR+ cells was negatively aVected by the presence of pathological HLA-DR¡ frequencies, especially in iDC (see representative histograms of patient 003 in Fig. 2c ). Supplemental Figure 1 shows pooled data from all patients for the experiments exempliWed in Fig. 2a-c. DC generated in the presence of MDSC are deWcient in antigen uptake Antigen uptake is a key function of DC, as it is a prerequisite for antigen processing and presentation to T cells. We found that the ability to take up antigen diminished with increasing numbers of HLA-DR¡ cells in iDC and mDC, in Wve of seven and Wve of six experiments, respectively (Fig. 3a, b) . Though this was not consistent at all time points, HLA-DR¡ cells often appeared less capable than HLA-DR+ cells to take up antigen. Figure 3c shows representative histograms from patients 003 and 004, exemplifying cases where HLA-DR¡ cells took up less (p003, day 2 + 5, p004 day 2 + 3) or more (p004 day 5 + 7) antigen. Comparison of cultures containing physiological (20%) or pathological (70%) HLA-DR¡ levels showed that high HLA-DR¡ frequencies could also impair the ability of HLA-DR+ cells to internalize FITC-dextran beads (Fig. 3d) .
Migration of iDC and mDC generated in the presence of CD14+HLA-DR¡ cells is impaired
To exert T-cell stimulatory capacity, it is crucial that antigen-loaded DC reach a lymph node. As DC vaccines are often applied intradermally, the ability of DC to actively migrate is likely to be of importance, even though this has remained diYcult to be studied in vivo. We used a transwell migration assay where the lower chamber contained the CCR7 ligands CCL19 and CCL21, and found that in the majority of cases both iDC and mDC generated in the presence of pathological (¸50%) levels of HLA-DR¡ cells showed reduced capacity to migrate compared to cultures free of HLA-DR¡ cells (Fig. 4a) . In DC generated with the 'fast-DC' protocol, the reduced migratory capacity could be explained by reduced CCR7 expression in cultures containing ¸50% HLA-DR¡ cells. However, when the 'long-DC' protocol was used, this was only observed in one out of four patients, while in the remaining patients CCR7 expression of most HLA-DR¡ containing cultures was equal or higher than in pure HLA-DR+ cultures. Pooled data of these experiments are shown in Fig. 4b . 
MDSC-DC can have impaired stimulatory capacity
The stimulation of T cells by in vitro-produced DC is the goal of all anti-cancer DC vaccines. To test the stimulatory capacity of DC generated in the presence of HLA-DR¡ cells, we used DC harvested on day 3 or 7 to stimulate allogeneic lymphocytes. Proliferation in response to allogeneic stimulation was weak in most cases and did not seem to diVer based on the HLA-DR¡/+ ratio in the DC cultures (Fig. 5a) . Interestingly, DC from long-DC cultures containing high frequencies (50% or above) of HLA-DR¡ cells exhibited a signiWcantly reduced capacity to stimulate IFN release of allogeneic T cells compared to DC generated from starting cultures containing physiological levels (0-35%) of HLA-DR¡ cells (Fig. 5b) . Stimulation with mDC generated by the short-DC protocol showed decreased IFN levels in response to pathological HLA-DR¡ frequencies in 6/9 experiments, though in most cases changes were minor and the diVerence was not signiWcant.
MDSC-DC exhibit altered cytokine production
To determine how HLA-DR¡ cells aVect the generation of mature functional DC and their stimulatory capacity, we studied the cytokine secretion of cultures containing physiological (0-20%) or pathological (70%) levels of HLA-DR¡ cells (Fig. 6a, b ). There was a striking interindividual variation of cytokine levels in both types of cultures, making it diYcult to assess changed patterns of cytokine secretion. Immature DC generated in the presence of pathological levels of HLA-DR¡ cells produced signiWcantly less IL-6 and MIP-1 , and displayed a tendency to secrete more IL-1 , IL-10 and IL-12(p40) and less IL-8 and IP-10 compared to iDC generated in the presence of low HLA-DR¡ numbers. No signiWcant diVerences in cytokine secretion of mDC were observed, though there was a trend toward lower IL-10 and IP-10 secretion in DC generated in the presence of pathological HLA-DR¡ levels. It should be noted that this cytokine luminex assay cannot distinguish between HLA-DR+ or HLA-DR¡ cells as the source of cytokine production.
We further investigated whether the production of oxidative stress could account for changes in DC phenotype and function after exposure to high levels of HLA-DR¡ cells. Oxidative stress levels in the myeloid cells were mostly constant between the cultures, with a slight tendency toward increased levels of oxidants in iDC generated in the presence of intermediate levels of HLA-DR¡ cells (Fig. 6c) . Compared to HLA-DR+ cells, HLA-DR¡ cells exhibited decreased levels of oxidative stress when tested ex vivo (Poschke, unpublished observation), but both populations exhibited similar levels of intracellular oxidation after in vitro culture (Fig. 6d) , suggesting that this was not the mechanism underlying DC dysfunction.
Discussion
DC vaccination is currently being tested in a great number of clinical trials. At the same time, monocyte-like CD14+HLA-DR¡/low MDSC have been shown to potently inXuence immune responses in various cancers [6] [7] [8] [9] [10] [11] [12] [13] [14] . We investigated whether the high frequencies of HLA-DR¡ cells often observed in cancer patient monocytes Two diVerent DC generation protocols, based on two DC vaccine clinical trials, were used in this study. The protocols diVer with regard to culture vessels, media, maturation stimuli and duration of culture. The fact that both protocols generate equivalent results when HLA-DR¡ cells are titrated into the starting population suggests that the negative eVect exerted by HLA-DR¡ cells is robust toward culture conditions and persists for a substantial amount of time in vitro.
In agreement with similar FSC/SSC characteristics in Xow cytometry (data not shown), CD14+HLA-DR¡/low cells appear to have a density similar to other CD14+ cells and, therefore, "contaminate" the monocyte population: isolated by elturiation and used for DC generation. This problem can even be anticipated when using other puriWcation methods, such as magnetic bead-based isolation of CD14+ cells, another monocyte isolation method commonly applied in DC vaccine protocols.
When we Wrst considered whether the presence of the CD14+HLA-DR¡/low immune-suppressive population during DC vaccine production could be an issue, we anticipated several possible scenarios: (1) even high numbers of HLA-DR¡ cell have no eVect on the quality and quantity of the generated vaccine, (2) HLA-DR¡ cells have a survival advantage or disadvantage and thereby aVect DC vaccine yield, (3) HLA-DR¡ cells aVect the quality of the vaccine product, either by their own disability to develop into DC or by aVecting diVerentiation and maturation of the entire culture. If HLA-DR¡ cells aVected cellular yield, this could easily be addressed by increasing the number of starting monocytes to achieve a suYcient number of vaccine doses. We did not observe a clear eVect of the presence of HLA-DR¡ cells on DC yield or viability. Instead, we found that the presence of HLA-DR¡ cells exhibited a dose-dependent negative eVect on DC maturation status and functional capacities. This is in agreement with Wang et al. [24] , who discovered that generation of DC from monocytes of myeloma patients was diYcult, while others observed no such diVerence [19] .
We found that markers aVected by the presence of high frequencies of HLA-DR¡ cells in DC cultures included the co-stimulatory molecules CD80 and CD86, the antigenpresentation molecule CD1a, as well as DC-Sign, which can provide co-stimulation, adhesion and act as a pattern Fig. 5 Stimulatory capacity of mDC generated from HLA-DR¡ containing cultures. Allogeneic lymphocytes were stimulated for 4 days with mDC generated by the long or short-DC protocol in the presence of physiological (0-35%) or pathological (50-70%) frequencies of HLA-DR¡ cells at a lymphocyte:DC ratio of 10:1. a Proliferation and b IFN production were assessed. Each line represents an allogeneic lymphocyte-DC pair; long-DC used were from p001 and p003 and short-DC were from patients p003, p004 and p005 recognition receptor. The exact function of CD83 on DC remains currently unknown, though this marker is considered to be one of the most important markers for monitoring DC maturation [25] . The observed phenotype suggests that DC generated in the presence of HLA-DR¡ cells are deWcient in sensing danger and in presentation of antigen in a stimulatory fashion. Fluorescent labeling of either HLA-DR¡ or HLA-DR+ cells allowed us to track surface marker expression and functional characteristics of both populations over time. Indeed, we found reduced antigen uptake in total and in originally HLA-DR¡ DC, further stressing that DC generated from HLA-DR¡ containing monocytes of cancer patients would have reduced capacity to induce antigen-speciWc T-cell responses in comparison to DC generated from mainly HLA-DR+ healthy donor monocytes. The reduced stimulatory capacity also manifested as the inferior ability of DC from HLA-DR¡ cell-containing cultures to stimulate allogeneic lymphocytes to produce IFN . The underlying mechanism for the observed changes remains to be deWned. Though we did detect impaired DC maturation and function, it is important to note that the suppressive CD14+HLA-DR¡/low melanoma MDSC are able to diVerentiate into DC and lose their suppressive capacity in the process. Even their cytokine production proWle as well as their production of oxidative stress indicates that they lose their MDSC properties during culture.
Particularly, the phenotypic defects were most pronounced in iDC, while diVerences between mDC generated from starting cultures containing high or low-levels of HLA-DR¡ cells were less severe, yet still detectable. There has been an ongoing debate whether iDC or mDC represent the most potent DC for use in vaccination [26] [27] [28] . Although iDC should naturally have superior migratory capacity and therefore are more likely to reach a lymph node, where exogenously loaded antigen can be presented to T cells, in vitro and in vivo studies now indicate the opposite to be the case [26, 28] . Further, vaccination with iDC requires DC to mature during migration, analogous to the in vivo situation where DC mature after antigen uptake and stimulation in the periphery. On the other hand, injection of fully mature and antigen-loaded DC promises optimal co-stimulatory activity that cannot be aVected by a potentially immune-suppressive tumor conditioned in vivo milieu.
Our Wndings suggest that the presence of HLA-DR¡ cells in starting cultures can aVect both iDC and mDC vaccines. It is possible that the negative eVect on iDC vaccines is stronger than on mDC vaccines, as the diVerences observed in iDC were stronger and the expected high migratory capacity was lacking. Strong maturation stimuli given in vitro could partially reverse the negative eVects of HLA-DR¡ cells on the mature phenotype, while potentially weaker maturation stimuli in vivo might not have the same eVect.
In conclusion, DC vaccine trials in cancers where CD14+HLA-DR¡ MDSC are known to occur will proWt from monitoring of this cell population. If monitoring reveals that DC vaccine products are less than optimal, or in patients with very high HLA-DR¡ frequencies (e.g., >50%) in the CD14+ population, removal of HLA-DR¡ cells should be beneWcial. One option to exclude HLA-DR¡ cells is positive selection of CD14+HLA-DR+ cells by Xuorescence-assisted cell sorting or magnetic bead isolation. Unfortunately, both methods are cost intensive to apply under conditions of clinical grade DC production and potentially modify cellular activation status as positive selection is necessary. Alternatively, a number of agents have been shown to reduce in vivo MDSC frequencies in patients and pre-clinical models [11, 17, [29] [30] [31] and could therefore potentially be used as a conditioning regimen prior to leukapheresis for collection of monocytes.
